BRIEF published on 02/27/2026 at 09:05, 6 days 9 hours ago Aiforia Technologies Oyj Anticipates Strong Clinical Revenue Growth Strategic Partnerships AI Technology Profitability Financial Growth Clinical Revenue
PRESS RELEASE published on 02/27/2026 at 09:00, 6 days 10 hours ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia Technologies Oyj's updated research report by NuWays AG reveals accelerated clinical revenue growth expectations, with key focus on AI technology adoption and strategic partnerships for sales growth NuWays AG Research Report Aiforia Technologies Oyj Clinical Revenue Growth AI Technology Adoption
BRIEF published on 02/11/2026 at 09:05, 22 days 9 hours ago Aiforia Technologies Oyj's Innovative Path to Profitability Profitability Medical Imaging Aiforia Technologies Vision Transformer Foundation Engine
PRESS RELEASE published on 02/11/2026 at 09:00, 22 days 10 hours ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia Technologies Oyj advances with new Foundation Engine technology for medical imaging, aiming for improved accuracy and scalability. Analyst recommends BUY with €3.80 target price Medical Imaging Scalability Accuracy Aiforia Technologies Oyj Foundation Engine
BRIEF published on 12/12/2025 at 09:05, 2 months 24 days ago Aiforia Technologies Strengthens Liquidity with Share Issuance Liquidity Share Issuance Cost Savings Growth Projections Aiforia Technologies
PRESS RELEASE published on 12/12/2025 at 09:00, 2 months 24 days ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia Technologies Oyj successfully completes directed share issuance, raising €4.2m to ease liquidity constraints. Company aims for sustainable cash generation with reduced operating expenses Cash Generation Operating Expenses Liquidity Constraints Aiforia Technologies Oyj Directed Share Issuance
BRIEF published on 10/23/2025 at 09:05, 4 months 13 days ago Aiforia Technologies Oyj Positioned as Pathology AI Leader Market Growth Diagnostic Accuracy Pathology AI Aiforia Technologies NuWays AG Rating
PRESS RELEASE published on 10/23/2025 at 09:00, 4 months 13 days ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia Technologies Oyj receives Buy recommendation for disrupting pathology with AI technology, leading in cancer diagnostics with AI-powered platform for faster, more accurate diagnoses AI-powered Platform Buy Recommendation Cancer Diagnostics Aiforia Technologies Oyj Pathology AI Technology
Published on 03/05/2026 at 17:55, 1 hour 10 minutes ago ACCESS Newswire to Host Fourth Quarter and Year End Earnings Conference Call on March 19, 2026
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 13:40, 5 hours 25 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 17:57, 1 hour 8 minutes ago EQS-Adhoc: Delivery Hero SE may redeem convertible bonds in H1 2026 using proceeds from a USD 1.5bn increase of its term loans subject to certain conditions
Published on 03/05/2026 at 17:48, 1 hour 16 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/05/2026 at 17:45, 1 hour 20 minutes ago Swiss Prime Site announces the conversion price of its CHF 350 million green convertible bonds due 2032 and the outcome of the incentivized conversion invitation
Published on 03/05/2026 at 18:40, 25 minutes ago 2025 Full-year results FREY: a pan-European platform already creating value
Published on 03/05/2026 at 18:34, 30 minutes ago Mersen: Number of shares and voting rights as of February 28, 2026
